FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897501868> ?p ?o ?g. }

• W2897501868 abstract "Lapatinib has clinical efficacy in the treatment of trastuzumab-refractory HER2-positive breast cancer. However, a significant proportion of patients develop progressive disease due to acquired resistance to the drug. Induction of apoptotic cell death is a key mechanism of action of lapatinib in HER2-positive breast cancer cells. We examined alterations in regulation of the intrinsic and extrinsic apoptosis pathways in cell line models of acquired lapatinib resistance both in vitro and in patient samples from the NCT01485926 clinical trial, and investigated potential strategies to exploit alterations in apoptosis signalling to overcome lapatinib resistance in HER2-positive breast cancer. In this study, we examined two cell lines models of acquired lapatinib resistance (SKBR3-L and HCC1954-L) and showed that lapatinib does not induce apoptosis in these cells. We identified alterations in members of the BCL-2 family of proteins, in particular MCL-1 and BAX, which may play a role in resistance to lapatinib. We tested the therapeutic inhibitor obatoclax, which targets MCL-1. Both SKBR3-L and HCC1954-L cells showed greater sensitivity to obatoclax-induced apoptosis than parental cells. Interestingly, we also found that the development of acquired resistance to lapatinib resulted in acquired sensitivity to TRAIL in SKBR3-L cells. Sensitivity to TRAIL in the SKBR3-L cells was associated with reduced phosphorylation of AKT, increased expression of FOXO3a and decreased expression of c-FLIP. In SKBR3-L cells, TRAIL treatment caused activation of caspase 8, caspase 9 and caspase 3/7. In a second resistant model, HCC1954-L cells, p-AKT levels were not decreased and these cells did not show enhanced sensitivity to TRAIL. Furthermore, combining obatoclax with TRAIL improved response in SKBR3-L cells but not in HCC1954-L cells. Our findings highlight the possibility of targeting altered apoptotic signalling to overcome acquired lapatinib resistance, and identify potential novel treatment strategies, with potential biomarkers, for HER2-positive breast cancer that is resistant to HER2 targeted therapies." @default.
• W2897501868 created "2018-10-26" @default.
• W2897501868 creator A5000509598 @default.
• W2897501868 creator A5001554361 @default.
• W2897501868 creator A5011649305 @default.
• W2897501868 creator A5015491002 @default.
• W2897501868 creator A5019124018 @default.
• W2897501868 creator A5021160836 @default.
• W2897501868 creator A5025907836 @default.
• W2897501868 creator A5027071974 @default.
• W2897501868 creator A5028010756 @default.
• W2897501868 creator A5030197973 @default.
• W2897501868 creator A5030497065 @default.
• W2897501868 creator A5032474505 @default.
• W2897501868 creator A5034794837 @default.
• W2897501868 creator A5050488184 @default.
• W2897501868 creator A5061321901 @default.
• W2897501868 creator A5070134628 @default.
• W2897501868 creator A5071432873 @default.
• W2897501868 creator A5072021902 @default.
• W2897501868 creator A5076159971 @default.
• W2897501868 creator A5081497371 @default.
• W2897501868 creator A5081819701 @default.
• W2897501868 creator A5086886026 @default.
• W2897501868 date "2018-10-11" @default.
• W2897501868 modified "2023-09-28" @default.
• W2897501868 title "Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL" @default.
• W2897501868 cites W1965317739 @default.
• W2897501868 cites W1969653304 @default.
• W2897501868 cites W1971288719 @default.
• W2897501868 cites W1979563875 @default.
• W2897501868 cites W1982590355 @default.
• W2897501868 cites W1983378923 @default.
• W2897501868 cites W1986688227 @default.
• W2897501868 cites W1992261705 @default.
• W2897501868 cites W1998872597 @default.
• W2897501868 cites W2007718868 @default.
• W2897501868 cites W2012784647 @default.
• W2897501868 cites W2013540451 @default.
• W2897501868 cites W2016334083 @default.
• W2897501868 cites W2036029010 @default.
• W2897501868 cites W2038969437 @default.
• W2897501868 cites W2040875703 @default.
• W2897501868 cites W2043463016 @default.
• W2897501868 cites W2047496509 @default.
• W2897501868 cites W2052170282 @default.
• W2897501868 cites W2055620948 @default.
• W2897501868 cites W2059854292 @default.
• W2897501868 cites W2060062311 @default.
• W2897501868 cites W2069626574 @default.
• W2897501868 cites W2072651545 @default.
• W2897501868 cites W2074521790 @default.
• W2897501868 cites W2078533623 @default.
• W2897501868 cites W2081098333 @default.
• W2897501868 cites W2086224272 @default.
• W2897501868 cites W2096913909 @default.
• W2897501868 cites W2107277218 @default.
• W2897501868 cites W2109439031 @default.
• W2897501868 cites W2110444464 @default.
• W2897501868 cites W2113931660 @default.
• W2897501868 cites W2121576318 @default.
• W2897501868 cites W2122118991 @default.
• W2897501868 cites W2124287743 @default.
• W2897501868 cites W2124812632 @default.
• W2897501868 cites W2129361678 @default.
• W2897501868 cites W2137132167 @default.
• W2897501868 cites W2141929347 @default.
• W2897501868 cites W2142990170 @default.
• W2897501868 cites W2145477245 @default.
• W2897501868 cites W2151264766 @default.
• W2897501868 cites W2151632284 @default.
• W2897501868 cites W2153215028 @default.
• W2897501868 cites W2153571329 @default.
• W2897501868 cites W2164302155 @default.
• W2897501868 cites W2168057516 @default.
• W2897501868 cites W2192080449 @default.
• W2897501868 cites W2243956249 @default.
• W2897501868 cites W2606094885 @default.
• W2897501868 cites W4247683600 @default.
• W2897501868 doi "https://doi.org/10.1186/s12885-018-4852-1" @default.
• W2897501868 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6180577" @default.
• W2897501868 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30305055" @default.
• W2897501868 hasPublicationYear "2018" @default.
• W2897501868 type Work @default.
• W2897501868 sameAs 2897501868 @default.
• W2897501868 citedByCount "17" @default.
• W2897501868 countsByYear W28975018682019 @default.
• W2897501868 countsByYear W28975018682020 @default.
• W2897501868 countsByYear W28975018682021 @default.
• W2897501868 countsByYear W28975018682022 @default.
• W2897501868 countsByYear W28975018682023 @default.
• W2897501868 crossrefType "journal-article" @default.
• W2897501868 hasAuthorship W2897501868A5000509598 @default.
• W2897501868 hasAuthorship W2897501868A5001554361 @default.
• W2897501868 hasAuthorship W2897501868A5011649305 @default.
• W2897501868 hasAuthorship W2897501868A5015491002 @default.
• W2897501868 hasAuthorship W2897501868A5019124018 @default.
• W2897501868 hasAuthorship W2897501868A5021160836 @default.
• W2897501868 hasAuthorship W2897501868A5025907836 @default.
• W2897501868 hasAuthorship W2897501868A5027071974 @default.

• next